Splice Bio
Barcelona, ES · 58 employees on LinkedIn · 9 known investors
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.
Founders & leadership
DV
Dr. Vila-PerellóCEO
DF
Dr. FrutosCo-founder
Investors · 9
Novartis Venture Fund✓ verifiedBasel · $5M – $25M
Roche Venture Fund✓ verifiedBasel · $648K – $3.2M
Sanofi Ventures✓ verifiedCambridge · $5M
Ysios Capital✓ verifiedBarcelona · $5.4M – $21.6M
Asabys Partners✓ verifiedMadrid
Criteria Bio VenturesBarcelona
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
EQT Life SciencesreportedLuxembourg · $11M – $66M
UCB VenturesreportedBrussels
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BJun 2025Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 3
by search overlap
AskBio20 shared keywordsAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.
Senti Biosciences19 shared keywordsSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
Bridgebio19 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Companies competing with Splice Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Splice Bio do?
- SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.
- Who founded Splice Bio?
- Splice Bio was founded by Dr. Vila-Perelló, Dr. Frutos.
- Who are Splice Bio's investors?
- Splice Bio's investors include Novartis Venture Fund, Roche Venture Fund, Sanofi Ventures, Ysios Capital, Asabys Partners, Criteria Bio Ventures, New Enterprise Associates (NEA), EQT Life Sciences and 1 more.
- Where is Splice Bio headquartered?
- Splice Bio is headquartered in Barcelona, ES.